Cell Lysis News and Research

RSS

Researchers develop new lab-on-a-chip platform that aims to improve pathogen detection

Nuclear amplification testing is commonly used for pathogen detection; however, the process is currently manually intensive and complex, and requires dedicated equipment. This prevents its use in some settings, and pathogen detection in individual samples.

24 Mar 2017

Decision-making process of tiniest viruses could lead to better treatments for diseases

Humans face hundreds of decisions every day. But we're not alone. Even the tiniest viruses also make decisions, and scientists are researching how they do so, to help lead to better treatments for some diseases.

7 Feb 2017

Valo Therapeutics develops novel oncolytic viral vaccines for treatment of multiple forms of cancer

A spin-out from the University of Helsinki, Valo Therapeutics is developing novel oncolytic viral vaccines for the treatment of multiple forms of cancer.

31 Jan 2017

Researchers provide insights into how phages exhibit high level of precision in cell destruction

Phage therapy, which exploits the ability of certain viruses to infect and replicate within bacteria, shows promise for treating antibiotic-resistant bacterial infections.

11 Jan 2017

Eppendorf Advantage supports smart, safe and stress-free environment for research labs

Eppendorf has announced the latest Advantage promotion period, until December 31st 2016, on a range of best-in-class solutions which drive productivity in the laboratory.

From Eppendorf 8 Sep 2016

Chromatrap describes methodologies to increase ChIP efficiency

Chromatrap, a business unit of Porvair Sciences, has published a new technical article that discusses and describes methodologies to increase Chromatin Immunoprecipitation efficiency by making sure chromatin in your samples is sheared to the correct size range.

From Chromatrap® - Porvair Sciences Ltd 19 Jul 2016

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

Amgen has announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. The extended indication marks the second approval for Kyprolis by the EC in less than a year.

6 Jul 2016

Fecal transplants transfer bacterial viruses that appear to be harmless to humans

Communities of viruses can be transferred during fecal transplants, according to a study published this week in mBio, an online open-access journal of the American Society for Microbiology. Fortunately for patients who use this procedure, the viruses found to be transmitted in this study appear to be harmless to humans.

30 Mar 2016

RUVICA (ibrutinib) capsules approved for treatment-naïve CLL patients

The U.S. Food and Drug Administration has approved IMBRUVICA (ibrutinib) capsules for treatment-naïve patients with chronic lymphocytic leukemia (CLL).

4 Mar 2016

Researchers reveal how stress conditions favor lytic reactivation of herpesviruses

Hiding their DNA genome inside the nucleus of the infected cells, the herpesviruses establish a lifelong infection in humans. Not well defined stress conditions are known to wake up these parasites from their dormancy - the latent phase - and reactivate the production of new viral progeny, eventually causing cell death by lysis - the lytic phase.

25 Feb 2016

Cardiac clot-busting drug decreases mortality in hemorrhagic stroke patients

Reporting on the results of a phase III international clinical trial, Johns Hopkins Medicine physicians say use of a cardiac clot-busting drug to treat strokes that cause brain bleeding safely decreased the death rate in patients by 10 percent, compared to a control group receiving saline.

23 Feb 2016

SillaJen reports initiation of multinational randomized Phase 3 study of Pexa-Vec in HCC patients

SillaJen, Inc., a private, clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, has announced the initiation of a multinational randomized Phase 3 open-label study of its lead product candidate, Pexa-Vec (formerly JX-594), in patients with advanced liver cancer, also known as hepatocellular carcinoma (HCC).

5 Jan 2016

UCSF researchers develop molecular 'on switch' that allows control over the actions of T cells

UC San Francisco researchers have engineered a molecular "on switch" that allows tight control over the actions of T cells, immune system cells that have shown great potential as therapies for cancer. The innovation lays the groundwork for sharply reducing severe, sometimes deadly side effects that have been a significant hurdle to advancing T cell-based treatments.

25 Sep 2015

Toxin pneumolysin causes progressive and fatal heart complications

Streptococcus pneumoniae is a major human pathogen and is known to be associated with increased risk of fatal heart complications including heart failure and heart attacks.

19 May 2015

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.

10 Mar 2015

Quanta obtains CE mark for portable, cartridge-based haemodialysis system

Quanta Fluid Solutions Ltd, a pioneering developer of advanced haemodialysis systems, announces it has received the CE mark for SC+, its portable, cartridge-based haemodialysis system.

6 Jan 2015

Study offers insights into mechanisms of bacterial resistance to antimicrobial peptides

Antimicrobial peptides are a distinctive class of potent, broad-spectrum antibiotics produced by the body's innate immune system--the first line of defense against disease-causing microbes.

18 Dec 2014

EPFL scientists discover two molecules that could overcome multidrug resistance in tuberculosis

Using a high-throughput screening assay, EPFL scientists have discovered two small molecules that could overcome the multidrug resistance of the bacterium that causes tuberculosis.

9 Oct 2014

LLNL scientists issued patent for producing antimicrobial compounds to fight superbugs

Superbugs, antibiotic-resistant bacteria, have been on the rise since antibiotics were first introduced 80 years ago. That's because these germ-fighting agents have lost their punch from being overprescribed and misused, allowing bacteria pathogens to develop immunities against them.

8 Oct 2014

Physician develops new device to treat stroke more effectively

A new device developed by a physician at the University of Arkansas for Medical Sciences and a researcher at the University of Arkansas at Little Rock could soon be available to treat stroke more effectively.

22 Aug 2014